Dragonfly Therapeutics Announces Multi-Target Expansion of its Research Collaboration with AbbVie to Develop Novel Therapeutic Candidates for Immune-Mediated Diseases

Dragonfly and AbbVie expand their existing collaboration in oncology and autoimmune disease to develop additional drug candidates in immune-mediated diseases using Dragonfly's proprietary Tri-specific NK cell Engager Therapy (TriNKET ) platform

- Dragonfly Therapeutics, Inc. ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, today announced an expansion of its research collaboration with ABBVie (NYSE: ABBV) to discover and develop Dragonfly's novel immunotherapies for new targets in autoimmune and fibrotic diseases. ABBVie successfully licensed its first TriNKET™ drug candidate from Dragonfly, part of a multi-target collaboration initiated in November 2019 in January 2021 .

"AbbVie is committed to delivering transformative treatment options for patients suffering from autoimmune and fibrotic diseases," said Dr. Jonathon Sedgwick , Vice President and Global Head of Discovery Research at AbbVie. "We have seen strong progress in our current collaboration with Dragonfly focused on their triNKET technology and are pleased to expand our partnership to include additional immunology targets of interest to AbbVie."

"AbbVie is a global leader in treating immune-mediated diseases, and they continue to be a terrific partner" said Bill Haney , co-founder and chief executive officer of Dragonfly, "we look forward to building on our successful collaboration, and rapidly progressing with the AbbVie team to advance new treatment options for patients."

Under the agreement, Dragonfly will grant AbbVie the option to license exclusive worldwide intellectual property rights to multiple new candidates developed using Dragonfly's TriNKET™ technology platform. AbbVie will pay Dragonfly an upfront payment, future success-based milestone payments and royalties.

About Dragonfly
Dragonfly Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel TriNKET™ technology to harness the body's innate immune system to bring breakthrough treatments to patients.

For more information visit:
www.dragonflytx.com
https://www.linkedin.com/company/dragonfly-therapeutics-inc
https://twitter.com/dragonflytx

DRAGONFLY MEDIA CONTACT:
Anne Deconinck | anne@dragonflytx.com

Related Links
https://www.dragonflytx.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-multi-target-expansion-of-its-research-collaboration-with-abbvie-to-develop-novel-therapeutic-candidates-for-immune-mediated-diseases-301528850.html

SOURCE Dragonfly Therapeutics, Inc.

News Provided by PR Newswire via QuoteMedia

ABBV
The Conversation (0)
Health Canada Approves AbbVie's RINVOQ®  for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at week 14 versus placebo 1 - RINVOQ is the first and only Janus Kinase (JAK) inhibitor approved to... Keep Reading...
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

- Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ ® ) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide (LINZESS ® ) in treating functional constipation in pediatric patients aged 6... Keep Reading...
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin... Keep Reading...

Latest Press Releases

Related News